Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Indolent Lymphoma-Pipeline Review, H1 2015

Indolent Lymphoma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Indolent Lymphoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Indolent Lymphoma-Pipeline Review, H1 2015', provides an overview of the Indolent Lymphoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Indolent Lymphoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Indolent Lymphoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Indolent Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Indolent Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Indolent Lymphoma Overview 9

Therapeutics Development 10

Pipeline Products for Indolent Lymphoma-Overview 10

Pipeline Products for Indolent Lymphoma-Comparative Analysis 11

Indolent Lymphoma-Therapeutics under Development by Companies 12

Indolent Lymphoma-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Unknown Stage Products 17

Indolent Lymphoma-Products under Development by Companies 18

Indolent Lymphoma-Companies Involved in Therapeutics Development 20

Amgen Inc. 20

Astellas Pharma Inc. 21

Bayer AG 22

BioMedics Japan Inc. 23

Biothera, Inc. 24

Boehringer Ingelheim GmbH 25

Celgene Corporation 26

Eagle Pharmaceuticals, Inc. 27

Emergent BioSolutions Inc. 28

F. Hoffmann-La Roche Ltd. 29

Gilead Sciences, Inc. 30

Incyte Corporation 31

Infinity Pharmaceuticals, Inc. 32

Juno Therapeutics Inc. 33

Kite Pharma, Inc. 34

MedImmune, LLC 35

Merck & Co., Inc. 36

Merck KGaA 37

MorphoSys AG 38

Pharmacyclics, Inc. 39

Sandoz Inc. 40

Indolent Lymphoma-Therapeutics Assessment 41

Assessment by Monotherapy Products 41

SAssessment by Target 42

Assessment by Mechanism of Action 44

Assessment by Route of Administration 46

Assessment by Molecule Type 48

Drug Profiles 50

bendamustine hydrochloride-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

bendamustine hydrochloride SI-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

BI-836826-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

blinatumomab-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

BM-ca-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

copanlisib-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

DI-B4-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

duvelisib-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

GS-9973-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

ibrutinib-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

idelalisib-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Imprime PGG-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

INCB-050465-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

INCB-39110-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

INCB-40093-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

JCAR-015-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

KTE-C19 CAR-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

lenalidomide-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

MEDI-551-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

MOR-208-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

obinutuzumab-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

otlertuzumab-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

rituximab biosimilar-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

vorinostat-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

Indolent Lymphoma-Recent Pipeline Updates 104

Indolent Lymphoma-Dormant Projects 158

Indolent Lymphoma-Discontinued Products 159

Indolent Lymphoma-Product Development Milestones 160

Featured News & Press Releases 160

Dec 01, 2014: Bayer To Present Phase II Clinical Trials Data On Copanlisib At ASH 56th Annual Meeting 160

Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG 160

Jan 22, 2014: New drug shows promise in treating indolent non-Hodgkin lymphomas 161

Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH 162

Dec 08, 2013: Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma 164

Feb 20, 2013: Phase 3 data published in The Lancet show bendamustine plus rituximab doubles progression-free survival in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma compared with CHOP-R 166

Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 167

Dec 03, 2012: Record number of bendamustine abstracts accepted for presentation at the Annual Meeting of the American Society of Hematology (ASH) 168

Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin's Lymphomas At ASH 169

Dec 05, 2010: Calistoga Reports Positive Phase I interim Results From Combination Trial Of CAL-101 In Hematologic Malignancies 171

Appendix 172

Methodology 172

Coverage 172

Secondary Research 172

Primary Research 172

Expert Panel Validation 172

Contact Us 172

Disclaimer 173

List of Tables

Number of Products under Development for Indolent Lymphoma, H1 2015 10

Number of Products under Development for Indolent Lymphoma-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Development by Companies, H1 2015 (Contd..1) 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Unknown Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Indolent Lymphoma-Pipeline by Amgen Inc., H1 2015 20

Indolent Lymphoma-Pipeline by Astellas Pharma Inc., H1 2015 21

Indolent Lymphoma-Pipeline by Bayer AG, H1 2015 22

Indolent Lymphoma-Pipeline by BioMedics Japan Inc., H1 2015 23

Indolent Lymphoma-Pipeline by Biothera, Inc., H1 2015 24

Indolent Lymphoma-Pipeline by Boehringer Ingelheim GmbH, H1 2015 25

Indolent Lymphoma-Pipeline by Celgene Corporation, H1 2015 26

Indolent Lymphoma-Pipeline by Eagle Pharmaceuticals, Inc., H1 2015 27

Indolent Lymphoma-Pipeline by Emergent BioSolutions Inc., H1 2015 28

Indolent Lymphoma-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 29

Indolent Lymphoma-Pipeline by Gilead Sciences, Inc., H1 2015 30

Indolent Lymphoma-Pipeline by Incyte Corporation, H1 2015 31

Indolent Lymphoma-Pipeline by Infinity Pharmaceuticals, Inc., H1 2015 32

Indolent Lymphoma-Pipeline by Juno Therapeutics Inc., H1 2015 33

Indolent Lymphoma-Pipeline by Kite Pharma, Inc., H1 2015 34

Indolent Lymphoma-Pipeline by MedImmune, LLC, H1 2015 35

Indolent Lymphoma-Pipeline by Merck & Co., Inc., H1 2015 36

Indolent Lymphoma-Pipeline by Merck KGaA, H1 2015 37

Indolent Lymphoma-Pipeline by MorphoSys AG, H1 2015 38

Indolent Lymphoma-Pipeline by Pharmacyclics, Inc., H1 2015 39

Indolent Lymphoma-Pipeline by Sandoz Inc., H1 2015 40

Assessment by Monotherapy Products, H1 2015 41

Number of Products by Stage and Target, H1 2015 43

Number of Products by Stage and Mechanism of Action, H1 2015 45

Number of Products by Stage and Route of Administration, H1 2015 47

Number of Products by Stage and Molecule Type, H1 2015 49

Indolent Lymphoma Therapeutics-Recent Pipeline Updates, H1 2015 104

Indolent Lymphoma-Dormant Projects, H1 2015 158

Indolent Lymphoma-Discontinued Products, H1 2015 159

List of Figures

Number of Products under Development for Indolent Lymphoma, H1 2015 10

Number of Products under Development for Indolent Lymphoma-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 16

Assessment by Monotherapy Products, H1 2015 41

Number of Products by Top 10 Targets, H1 2015 42

Number of Products by Stage and Top 10 Targets, H1 2015 42

Number of Products by Top 10 Mechanism of Actions, H1 2015 44

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 44

Number of Products by Top 10 Routes of Administration, H1 2015 46

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 46

Number of Products by Top 10 Molecule Types, H1 2015 48

Number of Products by Stage and Top 10 Molecule Types, H1 2015 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Amgen Inc.

Astellas Pharma Inc.

Bayer AG

BioMedics Japan Inc.

Biothera, Inc.

Boehringer Ingelheim GmbH

Celgene Corporation

Eagle Pharmaceuticals, Inc.

Emergent BioSolutions Inc.

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

Incyte Corporation

Infinity Pharmaceuticals, Inc.

Juno Therapeutics Inc.

Kite Pharma, Inc.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

MorphoSys AG

Pharmacyclics, Inc.

Sandoz Inc.

Indolent Lymphoma Therapeutic Products under Development, Key Players in Indolent Lymphoma Therapeutics, Indolent Lymphoma Pipeline Overview, Indolent Lymphoma Pipeline, Indolent Lymphoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com